Glenmark Life Sciences rebrands as Alivus Life Sciences

Mumbai: Glenmark Life Sciences, a developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, has announced its change of identity to Alivus Life Sciences.

This is consequent to the acquisition by Nirma Limited, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals. In March, Nirma acquired 91,895,379 equity shares, representing 75% of the current issued and paid-up equity share capital of Glenmark Life Sciences from Glenmark Pharmaceuticals.

Under the terms of the share purchase agreement, Nirma Limited purchased 75% of the current issued and paid-up equity share capital of Glenmark Life Sciences, consolidating its position as the new promoter of the company.

"The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space," the Company said in a press note.

"The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey," it added.

Read also: Glenmark Pharma USA unveils Lacosamide Oral Solution